Status:
COMPLETED
Diagnostic and Therapeutic Approaches to Hyperinflation and Small Airway Disease in COPD
Lead Sponsor:
Universitätsmedizin Mannheim
Conditions:
COPD
Eligibility:
All Genders
18+ years
Brief Summary
Current guideline-based criteria defining COPD do not meet the challenges set by the complex pathophysiology of the disease. Hyperinflation and affection of the small airways are two components that a...
Eligibility Criteria
Inclusion
- known or first diagnosis of COPD
- lung function testing consistent with hyperinflation or peripheral obstruction
- emphysema in imaging
- symptoms (dyspnea, cough, sputum) and risk factors (\>= 10 pack years)
- indication for bronchodilator therapy
Exclusion
- GOLD stages 3 and 4 (spirometric)
- indication for dual bronchodilator therapy, triple therapy or inhaled steroid
- contraindication for cardiopulmonary exercise testing
- unwilling to participate
Key Trial Info
Start Date :
October 2 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 11 2019
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT03287921
Start Date
October 2 2017
End Date
April 11 2019
Last Update
March 31 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Mannheim
Mannheim, Germany